Paying user area
Try for free
IQVIA Holdings Inc. pages available for free this week:
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Reportable Segments
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Operating Profit Margin since 2013
- Current Ratio since 2013
- Total Asset Turnover since 2013
- Price to Book Value (P/BV) since 2013
- Price to Sales (P/S) since 2013
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to IQVIA Holdings Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
ROA | = | 100 | × | Net income attributable to IQVIA Holdings Inc.1 | ÷ | Total assets1 | |
---|---|---|---|---|---|---|---|
Dec 31, 2022 | = | 100 | × | ÷ | |||
Dec 31, 2021 | = | 100 | × | ÷ | |||
Dec 31, 2020 | = | 100 | × | ÷ | |||
Dec 31, 2019 | = | 100 | × | ÷ | |||
Dec 31, 2018 | = | 100 | × | ÷ | |||
Dec 31, 2017 | = | 100 | × | ÷ | |||
Dec 31, 2016 | = | 100 | × | ÷ | |||
Dec 31, 2015 | = | 100 | × | ÷ | |||
Dec 31, 2014 | = | 100 | × | ÷ | |||
Dec 31, 2013 | = | 100 | × | ÷ |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
1 US$ in millions
The financial data indicates notable fluctuations and trends in the company's profitability and asset base over the ten-year period.
- Net Income Attributable to IQVIA Holdings Inc.
- The net income shows significant variability throughout the years. From 2013 to 2015, there is a general upward trend, increasing from 227 million USD in 2013 to 387 million USD in 2015. However, in 2016, net income drops sharply to 115 million USD, followed by a steep recovery in 2017 reaching a peak of 1,309 million USD. After this peak, net income declines substantially to 259 million USD in 2018 and continues to fluctuate moderately in the following years, with income figures oscillating between 191 million USD in 2019 and 1,091 million USD in 2022. This variation may suggest periods of exceptional gains or losses alongside operational volatility.
- Total Assets
- The total assets exhibit strong growth, especially from 2015 onwards. Beginning at 3,067 million USD in 2013, assets rise gradually to 3,926 million USD in 2015. A substantial jump occurs in 2016, where assets increase dramatically to 21,208 million USD, more than a fivefold increase compared to the prior year. Following this, asset values stabilize around the 22,000 to 25,000 million USD range for the subsequent years through 2022, indicating expansion and possible strategic acquisitions or investments that significantly increased the asset base.
- Return on Assets (ROA)
- ROA trends reflect the variations in net income relative to the asset growth. Initially, ROA improves, from 7.39% in 2013 up to 10.78% in 2014, then slightly dips to 9.86% in 2015. In 2016, ROA declines sharply to 0.54%, likely influenced by the dramatic increase in total assets paired with the substantial drop in net income. The subsequent years see ROA staying near low levels (around 0.82% to 1.15%) except for a moderate increase to 5.76% in 2017, coinciding with the peak in net income. Towards 2021 and 2022, ROA improves further to 3.91% and 4.31%, respectively, suggesting better asset utilization or recovery in profitability.
Overall, the company experienced substantial asset growth beginning in 2016, which was accompanied by significant volatility in net income and a corresponding impact on returns. This indicates potential structural changes or major investments influencing its financial profile. The ROA trend suggests challenges in efficiently leveraging the expanded asset base immediately after 2016, but gradual improvement in later years points toward an enhanced capacity to generate profits from assets.
Comparison to Competitors
IQVIA Holdings Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2022 | |||||||||||||
Dec 31, 2021 | |||||||||||||
Dec 31, 2020 | |||||||||||||
Dec 31, 2019 | |||||||||||||
Dec 31, 2018 | |||||||||||||
Dec 31, 2017 | |||||||||||||
Dec 31, 2016 | |||||||||||||
Dec 31, 2015 | |||||||||||||
Dec 31, 2014 | |||||||||||||
Dec 31, 2013 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
IQVIA Holdings Inc., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
IQVIA Holdings Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Dec 31, 2022 | ||
Dec 31, 2021 | ||
Dec 31, 2020 | ||
Dec 31, 2019 | ||
Dec 31, 2018 | ||
Dec 31, 2017 | ||
Dec 31, 2016 | ||
Dec 31, 2015 | ||
Dec 31, 2014 | ||
Dec 31, 2013 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Industry (Health Care)
IQVIA Holdings Inc. | Health Care | |
---|---|---|
Dec 31, 2022 | ||
Dec 31, 2021 | ||
Dec 31, 2020 | ||
Dec 31, 2019 | ||
Dec 31, 2018 | ||
Dec 31, 2017 | ||
Dec 31, 2016 | ||
Dec 31, 2015 | ||
Dec 31, 2014 | ||
Dec 31, 2013 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).